Protara Therapeutics (TARA) is now covered by JPMorgan Chase & Co.. They set an "overweight" rating and a $27.00 price target on the stock.
Protara Therapeutics Highlights TARA-002 NMIBC Data, FDA Plans for Lymphatic Malformations at Oppenheimer Conf [Yahoo! Finance]
TARA-002 Demonstrates 68% Complete Response Rate at Six Months in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
Protara Therapeutics to Participate in Upcoming Investor Conferences [Yahoo! Finance]
Protara Therapeutics to Participate in Upcoming Investor Conferences